华森制药：药品生产许可证变更及通过GMP符合性检查

Core Viewpoint - Huason Pharmaceutical has received a new drug production license and passed GMP compliance checks, which will enhance production capacity but will not significantly impact short-term performance [1] Group 1: Regulatory Changes - The company announced the receipt of a new drug production license from the Chongqing Drug Administration [1] - Two products, including injectable Esomeprazole Sodium, have been added to the production license [1] Group 2: GMP Compliance - The small-scale synthesis production line in the Rongchang Industrial Park has passed the GMP compliance check [1] - Both injectable Esomeprazole Sodium and the raw material drug (Agomelatine) have successfully passed GMP compliance checks [1] Group 3: Impact on Operations - These changes are expected to improve the company's capacity utilization and promote large-scale production [1] - However, the company does not anticipate a significant impact on its performance in the short term [1]